Journal Article

Determinants of Treatment Response to Sulfadoxine-Pyrimethamine and Subsequent Transmission Potential in Falciparum Malaria

Fabián Méndez, Álvaro Muñoz, Gabriel Carrasquilla, Diana Jurado, Myriam Arévalo-Herrera, Joseph F. Cortese and Christopher V. Plowe

in American Journal of Epidemiology

Published on behalf of Johns Hopkins Bloomberg School of Public Health

Volume 156, issue 3, pages 230-238
Published in print August 2002 | ISSN: 0002-9262
Published online August 2002 | e-ISSN: 1476-6256 | DOI:
Determinants of Treatment Response to Sulfadoxine-Pyrimethamine and Subsequent Transmission Potential in Falciparum Malaria

More Like This

Show all results sharing this subject:

  • Public Health and Epidemiology


Show Summary Details


Drug resistance is contributing to increasing mortality from malaria worldwide. For assessment of the role of resistance-conferring parasite mutations on treatment responses to sulfadoxine-pyrimethamine (SP) and transmission potential, 120 subjects with uncomplicated falciparum malaria from Buenaventura, Colombia, were treated with SP and followed for 21 days in the period February 1999 to May 2000. Exposures of interest were mutations in Plasmodium falciparum dihydrofolate reductase (DHFR) and dihydropteroate synthase that confer resistance to pyrimethamine and sulfadoxine, respectively. Although SP was highly efficacious (96.7%), the presence together of DHFR mutations at codons 108 and 51 was associated with longer parasite clearance time (relative hazard = 0.24, p = 0.019) more so than the 108 mutation alone (relative hazard = 0.45, p = 0.188). This association remained after controlling for potential confounders. Infections with these mutations were also associated with the presence of gametocytes, the sexual form of the parasite responsible for transmission, 14 and 21 days after treatment (p = 0.016 and p = 0.048, respectively). Higher gametocytemia is probably due to DHFR mutations prolonging parasite survival under drug pressure, resulting in longer parasite clearance time and allowing asexual parasites to differentiate into gametocytes. These results suggest that even when SP efficacy is high, DHFR mutations that are insufficient to cause therapeutic failure may nevertheless increase malaria transmission and promote the spread of drug resistance. Am J Epidemiol 2002;156:230–8.

Keywords: dihydropteroate synthase; drug resistance; malaria; Plasmodium falciparum; pyrimethamine; sulfadoxine; Abbreviations: DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; PCT, parasite clearance time; SP, sulfadoxine-pyrimethamine; WHO, World Health Organization.

Journal Article.  5315 words.  Illustrated.

Subjects: Public Health and Epidemiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.